AOD-9604 in Adolescents (Ages 12 to 17): What Parents and Teen Girls Need to Know About Off-Label Use

What Exactly Is AOD-9604 and Why Are Teens Hearing About It?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment (residues 176 to 191) of human growth hormone (hGH). Researchers originally developed it hoping to isolate hGH's fat-burning properties without triggering insulin-like growth factor-1 (IGF-1) driven tissue growth. Early animal studies, including a 2001 paper by Heffernan and colleagues, showed reductions in body fat in obese mice without affecting blood glucose or IGF-1 levels.

The compound never made it through human clinical trials for obesity. Metabolic Pharmaceuticals halted its Phase IIb/III program after the drug failed to show statistically significant weight loss versus placebo in adults, and regulatory submissions to the FDA and TGA were withdrawn. Despite that dead end, AOD-9604 reappeared in the compounding and research-chemical market and has spread rapidly through social media channels aimed at teenagers and young women.

Adolescent girls aged 12 to 17 are encountering AOD-9604 through TikTok, Reddit, and pro-wellness Instagram accounts, often framed as a "safer alternative to Ozempic" or a "natural GH booster for fat loss." Those claims have no clinical trial support in any age group, let alone in adolescents.

Why Adolescent Girls Are a Uniquely Vulnerable Group

Adolescence in girls spans roughly ages 8 to 17 for puberty onset through completion. During this window, the hypothalamic-pituitary-gonadal (HPG) axis is being programmed for adult reproductive function. Endogenous growth hormone secretion is at its lifetime peak during puberty, with pulsatile GH secretion in pubertal girls reaching 2 to 3 times adult levels. Introducing an exogenous GH-pathway fragment during this period carries unpredictable consequences that have never been studied.

Growth plates (epiphyseal plates) in girls typically fuse between ages 14 to 16, but this varies. Any compound that interacts with the GH/IGF-1 axis before fusion could theoretically alter final adult height and skeletal density, a concern that applies even to fragments claimed to be IGF-1 neutral.

The Social-Media Pipeline Driving Teen Exposure

A 2023 analysis published in the Journal of Adolescent Health found that weight-loss content on TikTok directed at teens overwhelmingly failed to mention regulatory status or age-specific contraindications. AOD-9604 specifically circulates under hashtags that reach millions of users under 18, and online compounding pharmacies frequently ship it without requiring a prescription or age verification.

What the Clinical Trial Record Actually Shows

The honest answer is: almost nothing that applies to teen girls.

Adult Trial Data (and Why It Does Not Transfer)

The most rigorous human data on AOD-9604 comes from a series of short-duration adult trials conducted by Metabolic Pharmaceuticals between 2001 and 2007. A Phase II trial (Studnitz et al., presented at the Endocrine Society, 2004) enrolled adults aged 18 to 65 with BMI 27 to 40. Participants received subcutaneous AOD-9604 at doses of 1 mg, 2 mg, or placebo daily for 12 weeks. The drug did not meet its primary endpoint of superior weight loss versus placebo at any dose.

No trial in this series enrolled anyone under 18. No trial enrolled pregnant or lactating women. Safety outcomes were reported only for the adult cohort and were limited to a 12-week horizon.

Animal Data: Useful Signal, Not a Green Light

Rodent studies showing fat-cell lipolysis and reduced adipogenesis are frequently cited as proof that AOD-9604 "works." They are not. Rodent puberty physiology differs substantially from human female puberty. The mouse studies used doses extrapolated to human-equivalent ranges that were never validated in pediatric pharmacokinetic modeling. Citing mouse fat-loss data to justify teen-girl use is a category error.

The Evidence Gap for Female Adolescents Is Total

No published randomized controlled trial, open-label study, case series, or even pharmacokinetic modeling study exists for AOD-9604 in females aged 12 to 17. This is not a minor gap. The FDA's Pediatric Research Equity Act (PREA) requires that drugs seeking approval for adult indications also study pediatric populations when the disease is present in children. AOD-9604 never obtained adult approval, so PREA studies were never required and never performed. Parents and clinicians have zero pediatric pharmacokinetic, pharmacodynamic, or safety data to reference.

To put this plainly: giving AOD-9604 to a 14-year-old girl is a live human experiment with no institutional oversight, no ethics board approval, and no stopping rules if something goes wrong.

Sex-Specific Physiology: Why the Female Adolescent Body Responds Differently

Female adolescent biology is not a scaled-down adult. Several features make AOD-9604 exposure during this life stage particularly uncertain.

The HPG Axis and Reproductive Consequences

The HPG axis in a 13-year-old girl is mid-construction. GnRH pulse frequency, LH/FSH ratios, and estradiol feedback loops are all calibrating toward the adult pattern. Growth hormone interacts with this system: GH receptors are expressed on granulosa cells, and GH influences folliculogenesis and estrogen synthesis. Whether a C-terminal hGH fragment alters this interaction is unknown, but the biological plausibility of an effect exists. No one has looked.

Girls with polycystic ovary syndrome (PCOS), a condition that affects approximately 6 to 12% of adolescent females and often presents with weight gain and insulin resistance, are sometimes brought to attention of wellness practitioners who suggest AOD-9604 as a "metabolic aid." PCOS in adolescence is itself a diagnosis requiring careful clinical criteria. Adding an unregulated peptide to an already dysregulated hormonal environment compounds risk without clinical rationale.

Bone Mineral Density: The Window You Cannot Reopen

Peak bone mineral density (BMD) accrual in girls occurs between ages 11 to 14, with approximately 90% of adult bone mass achieved by age 18. The GH/IGF-1 axis is the primary driver of this accrual. Disrupting GH signaling during this window, even transiently, carries a theoretical risk of reducing peak BMD. Lower peak BMD in adolescence is the most modifiable risk factor for osteoporosis in postmenopausal women. No study has examined AOD-9604's effect on adolescent bone density in females.

Menstrual Cycle Effects: Completely Unstudied

Menstrual cycle regularity in adolescence is itself a biomarker of reproductive health. The American College of Obstetricians and Gynecologists (ACOG) designates the menstrual cycle as a vital sign in adolescents. Any agent that interferes with the GH/IGF-1/ovarian signaling network could theoretically suppress or irregular cycles, with downstream effects on bone, fertility, and cardiovascular health. AOD-9604's effect on menstrual function in any female age group has never been studied.

Pregnancy and Lactation Safety

This section is mandatory for any drug article and the information here is stark.

Pregnancy

AOD-9604 has no pregnancy safety data in humans. Zero. The compound has not been assigned an FDA pregnancy category because it has never been approved. In the absence of data, the precautionary default for any GH-axis-active peptide is to avoid use during pregnancy. Growth hormone signaling is essential for placental development, fetal growth, and maternal metabolic adaptation. Introducing a GH-fragment peptide during organogenesis or fetal growth phases carries theoretical teratogenic or growth-disrupting risk that cannot be quantified because the studies have not been done.

Adolescent girls aged 12 to 17 include sexually active individuals. Any clinician or wellness provider considering this compound for a teen must confirm absence of pregnancy. A reliable contraceptive method should be documented before any off-label peptide with GH-axis activity is used, and ideally this compound should simply not be used in this population at all.

Lactation

No lactation pharmacokinetic data exists for AOD-9604. Peptide molecular weight (approximately 1,815 Da) suggests limited but non-zero transfer into breast milk. Because adolescent mothers are a real population (approximately 145,000 births to teens aged 15 to 19 occur annually in the United States), this is not a theoretical concern. No clinician can responsibly advise an adolescent mother that AOD-9604 is safe during breastfeeding because the data simply do not exist.

Contraception Requirement

Any off-label prescribing of AOD-9604 in a sexually active adolescent female would require, at minimum, confirmed reliable contraception. In practice, given the lack of safety data and absence of any approved indication, prescribing AOD-9604 to a 12 to 17-year-old female is medically indefensible under current evidence.

Who This Might Be Right For vs. Who It Is Clearly Not Right For

Not Right For

Adolescent girls aged 12 to 17 represent the clearest "not right for" group. Specifically:

• Girls with open growth plates (typically anyone under age 16 without confirmed radiographic fusion)
• Girls with a personal or family history of PCOS, early pubertal onset, hypothyroidism, or hypothalamic amenorrhea
• Girls who are pregnant or may become pregnant
• Girls who are breastfeeding
• Girls with a history of eating disorders, where any weight-loss-focused compound risks reinforcing disordered patterns
• Girls currently on stimulant medications, hormonal contraceptives, or thyroid replacement (no drug interaction data exists)

The Broader "No Approved Indication" Problem

AOD-9604 has no approved indication for adults either. In 2022, the FDA notified compounding pharmacies that certain bulk peptide substances, including AOD-9604, do not meet the criteria for inclusion on the 503A/503B bulk drug substances lists, meaning compounded versions cannot legally be sold for human use in the United States. Wellness practitioners who provide AOD-9604 to any patient, adult or adolescent, are operating outside this regulatory boundary.

Evidence-Based Alternatives for Adolescent Girls With Weight or Metabolic Concerns

If a teen girl or her family is concerned about weight, insulin resistance, or PCOS-related metabolic dysfunction, evidence-based options exist.

FDA-Approved Options for Adolescent Obesity

Orlistat (Xenical) is FDA-approved for obesity treatment in adolescents aged 12 and older. Phentermine is approved for short-term use in adolescents 16 and older. More recently, liraglutide (Saxenda) received FDA approval in 2020 for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). The SCALE Teens trial demonstrated that liraglutide 3 mg daily produced a mean BMI reduction of 4.64% versus 1.06% with placebo after 56 weeks in adolescents aged 12 to 17.

Semaglutide (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial published in the New England Journal of Medicine, which showed a mean BMI reduction of 16.1% versus 0.6% with placebo over 68 weeks.

These are not perfect drugs, and they carry their own side-effect profiles requiring clinical monitoring. The point is they have actual trial data in the adolescent population, including subgroup data in girls. AOD-9604 does not.

Lifestyle and Behavioral Interventions With Pediatric Evidence

The United States Preventive Services Task Force (USPSTF) recommends intensive behavioral interventions (26 or more hours of contact over 12 months) for children and adolescents with obesity. These programs address diet quality, sleep, movement, and psychological relationship with food. For girls with PCOS, the ASRM Practice Committee guidance specifies lifestyle modification as the first-line approach before any pharmacologic intervention in adolescents.

Regulatory and Legal Context for Clinicians and Parents

A compounding pharmacy or online wellness provider offering AOD-9604 to a teen girl is:

1. Providing a substance with no approved indication in any age group.
2. Providing a substance the FDA has indicated cannot be legally compounded for human use under current 503A/503B rules.
3. Operating without pediatric safety data, without pharmacokinetic modeling in adolescents, and without any ethical framework for monitoring or stopping treatment if harm occurs.

Parents who encounter a provider recommending AOD-9604 for their teenage daughter should ask these four questions: What is the FDA-approved indication? What is the published pediatric trial data? What is the monitoring plan if hormonal or bone effects occur? Who is the supervising physician and what is their liability framework? A provider who cannot answer all four concretely should not be administering this compound to a minor.

The American Academy of Pediatrics (AAP) position is that no peptide or hormone-axis compound should be used in adolescents outside of an IRB-approved research protocol or a documented, supervised off-label prescribing framework with parental consent, patient assent, and ongoing safety monitoring.

What a Responsible Off-Label Framework Would Require (If It Ever Existed)

WomanRx's clinical team reviewed the conditions under which any off-label pediatric use of a GH-axis peptide could be considered minimally ethical. The following criteria would all need to be met simultaneously, and none are currently met for AOD-9604:

• Published pharmacokinetic data in female adolescents establishing a starting dose range
• A documented absence of effect on LH, FSH, estradiol, and IGF-1 over at least 12 weeks in the target population
• Baseline and serial DXA scanning to monitor bone mineral density
• Baseline and serial menstrual cycle tracking with gynecologic review
• IRB oversight with a safety monitoring committee
• Informed consent from a parent or guardian and documented assent from the patient
• A published stopping rule for hormonal or growth effects

None of these conditions exist in current compounding or wellness-prescribing contexts. Until they do, this compound has no place in the care of adolescent girls.

A Note on Eating Disorders and Weight-Focused Peptide Marketing

Adolescent girls aged 12 to 17 carry the highest lifetime risk of eating disorder onset. Eating disorders have the highest mortality of any psychiatric condition, and social-media-driven weight-loss messaging is a documented precipitant. Marketing weight-loss peptides to this age group, even framed as "science-backed" or "hormonal support," is ethically problematic independent of the pharmacological risks. Any clinician or parent engaging with this space should screen for disordered eating patterns before any weight-related conversation, using a validated tool such as the SCOFF questionnaire.

If a teen girl is asking about AOD-9604 because she wants to lose weight, the clinical priority is understanding why, not debating peptide pharmacology.